Gestational Trophoblastic Neoplasia

Lurain, John R.

doi:10.1007/0-387-31056-8_51

Cited by 3 publications

(4 citation statements)

References 90 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus was also found to have a codon 987 mutation in Pol, which conferred cross-resistance to cidofovir (23). Later, another laboratory-derived ganciclovir-resistant CMV strain was also found to have a mutation in UL97, at codon 460 (24).…”

Section: Analysis Of Mutations In Drug-resistant CMVmentioning

confidence: 99%

Antiviral drug resistance in human cytomegalovirus

Chou

1999

Transplant Infectious Dis

View full text Add to dashboard Cite

Drug-resistant cytomegalovirus (CMV) should be considered when viral shedding persists after several weeks of therapy. The problem is most likely to arise in the setting of a severely immunosuppressed host with continuing or relapsing disease. Not all treatment failure can be attributed to drug resistance. The testing of CMV isolates for drug resistance in cell culture is time-consuming and labor-intensive, but recent advances in understanding of the genetics of resistance have resulted in rapid genotypic assays for specific mutations in the viral UL97 phosphotransferase or UL54 DNA polymerase genes that can predict resistance and cross-resistance to specific drugs. This information may help in the selection of alternative therapy.

show abstract

Section: Analysis Of Mutations In Drug-resistant CMVmentioning

confidence: 99%

Antiviral drug resistance in human cytomegalovirus

Chou

1999

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…BSA was calculated using the Mosteller formula: BSA metres 2 ÀÁ ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi height centimetres ðÞ Â weight kg ðÞ 3600 q [22].…”

Section: Discussionmentioning

confidence: 99%

“…Using the sum of eight risk-factors, FIGO is designed to predict the risk of primary, single-agent chemotherapy resistance, stratifying patients into low-(score ⩽6) and high-risk groups (score ⩾7). In the United Kingdom (UK), low-risk (LR-GTN) patients are typically treated with first-line single-agent methotrexate (MTX) [1], employing a MTX-FA 8-day regimen, whilst high-risk (HR-GTN) patients receive first-line combination chemotherapy, usually with EMA/CO (etoposide, methotrexate, dactinomycin, cyclophosphamide and vincristine [1][2][3]). Despite FIGO classification, a third of patients treated for LR-GTN are resistant to first-line MTX-FA, increasing to four out of five of those scoring 5 or 6 [4,5].…”

Section: Introductionmentioning

confidence: 99%

Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia

Parker¹,

Cushen²,

Hills³

et al. 2023

Gynecologic Oncology

View full text Add to dashboard Cite

“…For the past 50 years, advances in the diagnosis and management of GTD has developed to a point where there are low morbidity and mortality when the principles of therapy are applied. 1 This study was undertaken to describe the hospital-based prevalence rate of GTD and to discuss the changing trends in its management in the past 8 years in the hope of continuously providing improved care for women afflicted with this condition in our part of India.…”

Section: Introductionmentioning

confidence: 99%